Brii Bio Presents Late-Breaking Data from Its Phase 2 ENRICH and ENHANCE Studies at AASLD 2026, Supporting BRII-179-Based Priming and Enrichment Strategy for HBV Functional Cure

Data across five Phase 2 studies of BRII-179, including ENSURE, ENRICH and ENHANCE, support its potential to prime HBV-specific immune responses and improve functional cure rates when used with siRNA-based therapies. ENRICH prospectively reproduced the previously observed priming effect; the excerpt provides no numerical efficacy results.